Taxoprexin® Treatment for Advanced Eye Melanoma
To evaluate objective response rate and duration of response to weekly Taxoprexin®.
To evaluate the safety profile of weekly Taxoprexin® in this patient population.
To evaluate overall survival in the same patient population. To evaluate time to disease progression, and the time to treatment failure in patients with metastatic choroidal melanoma being treated with weekly Taxoprexin® Injection.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase II Open-Label Study of Weekly Taxoprexin® (DHA-Paclitaxel) Injection as Treatment of Patients With Metastatic Uveal (Choroidal) Malignant Melanoma|
- Response Rate
- Time to progression
- Time to treatment failure
|Study Start Date:||October 2005|
|Estimated Study Completion Date:||April 2007|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00244816
|United States, Texas|
|MD Anderson Cancer Center|
|Houston, Texas, United States, 77030-4009|
|Study Director:||Agop Bedikian, MD||M.D. Anderson Cancer Center|